Abstract: The present invention provides methods for treating and preventing the onset of Pneumocytis carinii pneumonia (PCP) comprising administering to a mammal in need of such treatment or prevention an effective amount of a pharmaceutically acceptable iron chelator. This invention also provides a method for treating or preventing the onset of PCP comprising administering to a mammal in need of such treatment or prevention a composition comprising the following components: (a) a pharmaceutically acceptable iron chelator; (b) a compound selected from trimethoprim/sulfamethoxazole and pentamidine; and (c) a pharmaceutically compatible carrier or diluent, wherein the amounts of said component (a) and said component (b) in combination are effective in treating said pneumonia. Also provided is a composition for the treatment or prevention of PCP.

Abstract: The present invention provides methods for treating and preventing the onset of Pneumocystis carinii pneumonia (PCP) comprising administering to a mammal in need of such treatment or prevention an effective amount of a pharmaceutically acceptable iron chelator. This invention also provides a method for treating or preventing the onset of PCP comprising administering to a mammal in need of such treatment or prevention a composition comprising the following components: (a) a pharmaceutically acceptable iron chelator; (b) a compound selected from trimethoprim/sulfamethoxazole and pentamidine; and (c) a pharmaceutically compatible carrier or diluent, wherein the amounts of said component (a) and said component (b) in combination are effective in treating said pneumonia. Also provided is a composition for the treatment or prevention of PCP.

Abstract: The present invention provides methods for treating and preventing the onset of Pneumocystis carinii pneumonia (PCP) comprising administering to a mammal in need to such treatment or prevention an effective amount of a pharmaceutically acceptable iron chelator. This invention also provides a method for treating or preventing the onset of PCP comprising administering to a mammal in need of such treatment or prevention a composition comprising the following components: (a) a pharmaceutically acceptable iron chelator; (b) a compound selected from trimethoprim/sulfamethoxazole and pentamidine; and (c) a pharmaceutically compatible carrier or diluent, wherein the amounts of said component (a) and said component (b) in combination are effective in treating said pneumonia. Also provided is a composition for the treatment or prevention of PCP.

Abstract: A composition comprising from 0.02 to 17 parts by weight of glycerol per part by weight of an iron chelating agent selected from the group consisting of salicyl hydroxyamic acid; 2,3- and 3,4-dihydroxy benzoic acid; and halobenzohydroxamic; e.g., m-iodobenzohydroxamic acid and m-chlorobenzohydroxamic acid; as well as their C.sub.1 to C.sub.4 alkyl esters. When this composition is administered parenterally, it is found to block aerobic and anaerobic glucose catabolism and thereby accomplish control of several trypanosomes, including Trypanosoma brucei, T. gambiensi, T. rhodesiensi, T. equiperdum, T. evansi, T. congolense and T. vivax. In mammals, the therapeutic dosage is calculated to provide at least 138 mg/kg of body weight of glycerol and at least 96 mg/kg of body weight of the iron chelating agent.